The BERIL-1 study only showed a trend toward improved ORR in the PI3Kα-activated subgroup recognizing the small number of mutationally selected patients in the study, whereas both of our patients with alterations in mTOR/Akt or PTEN loss showed disease stability.
← all excerpts
Duvelisib with Docetaxel for Patients with Anti-PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma.
1
—
—